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How Are Sleep Characteristics Related to Cardiovascular Health?
Results From the Population-Based HypnoLaus study
Nadine H€ausler, PhD; Pedro Marques-Vidal, MD, PhD; Raphael Heinzer, MD, MPH;* Jose Haba-Rubio, MD, PhD*
Background-—Although sleep characteristics have been linked to cardiovascular disease and cardiovascular risk factors, the
association between sleep characteristics measured by polysomnography and cardiovascular health (CVH) remains unknown.
Methods and Results-—In a population-based sample (n=1826), sleep characteristics were assessed by both sleep questionnaires
and polysomnography. Global, behavioral, and biological CVH were deﬁned according to the American Heart Association.
Multinomial logistic regressions were performed to estimate relative risk ratios and 95% CI. Strong dose-response associations
were found between all oxygen saturation–related variables (oxygen desaturation index, mean oxygen saturation, and percentage
of total sleep time spent under 90% oxygen saturation) and obstructive sleep apnea (severity categories and apnea/hypopnea
index) and global, behavioral, and biological CVH. Mean oxygen saturation had the strongest positive association (relative risk
ratios 1.31 [CI 1.22-1.41]; 1.78 [CI 1.55-2.04] for intermediate relative to ideal CVH), and oxygen desaturation index had the
strongest negative association (relative risk ratios 0.71 [CI 0.65-0.78]; 0.45 [CI 0.34-0.58] for intermediate relative to ideal CVH)
with global CVH, and these associations were also the most robust in sensitivity analyses. The impacts of sleep architecture and
sleep fragmentation were less consistent.
Conclusions-—Mean oxygen saturation, oxygen desaturation index, and apnea/hypopnea index were associated with CVH.
Conversely, most variables related to sleep architecture and sleep fragmentation were not consistently related to CVH. Sleep-
disordered breathing and the associated oxygen (de)saturation were associated with CVH more strongly than with sleep
fragmentation. ( J Am Heart Assoc. 2019;8:e011372. DOI: 10.1161/JAHA.118.011372.)
Key Words: cardiovascular disease prevention • cardiovascular health • mean oxygen saturation • oxidative stress • oxygen
desaturation index • polysomnography • sleep
C ardiovascular disease is the leading cause of mortalityworldwide.1 Although a sizable fraction of cardiovascular
disease events could be prevented by simple measures,2
preventive measures toward cardiovascular disease are still
insufﬁciently implemented.3 Recently, the American Heart
Association has reemphasized the need for primordial pre-
vention, ie, the prevention of cardiovascular risk factors, to
promote cardiovascular health (CVH).4 Indeed, several popu-
lation-based cohort studies have demonstrated the impor-
tance of the CVH concept, as they found substantial risk
reductions in cardiovascular disease incidence and mortality
for subjects with ideal CVH compared with those with poor
CVH.5,6 The American Heart Association deﬁned 4 behavioral
(smoking status, body mass index [BMI], physical activity, diet)
and 3 biological (fasting blood glucose, total cholesterol, blood
pressure) cardiovascular risk factors to assess CVH.4 Thus,
behavioral CVH is modiﬁable by lifestyle changes, whereas a
change in biological CVH usually requires pharmacological
interventions.
Sleep-related disorders such as obstructive sleep apnea,
excessive daytime sleepiness, and insufﬁcient sleep are highly
prevalent in the population7-9 and have been associated with
cardiovascular disease.7 In a recent review several sleep
characteristics including obstructive sleep apnea, excessive
daytime sleepiness, and insufﬁcient sleep were linked with
cardiovascular risk factors such as obesity, sedentary
lifestyle, poor diet, diabetes mellitus, and high blood pres-
sure.7 Although some sleep characteristics measured by
polysomnography (PSG) have previously been associated with
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cardiovascular disease10 and with some cardiovascular risk
factors,7,11,12 no study has ever assessed the effect of sleep
characteristics measured by PSG on CVH.
Hence, we aimed to investigate the association between
various sleep characteristics measured by questionnaire and
by PSG and CVH. We hypothesized that subjects with optimal
sleep characteristics were more likely to have ideal CVH
compared with people with poor sleep characteristics or sleep
disorders such as obstructive sleep apnea or excessive
daytime sleepiness.
Methods
Due to the sensitivity of the data and the lack of consent for
online posting, individual data cannot be made accessible.
Only metadata will be made available in digital repositories.
Metadata requests can also be performed via the study
website (www.colaus-psycolaus.ch).
Population Sampling
HypnoLaus is a population-based sleep cohort study con-
ducted in Lausanne, Switzerland. The HypnoLaus study was
performed between September 1, 2009 and June 30, 2013,
and participants were recruited among the CoLaus/PsyCo-
Laus study.13 This observational prospective study was
conducted to assess the prevalence and determinants of
cardiovascular risk factors and cardiovascular disease and to
identify new determinants of these risk factors. Participants of
the CoLaus/PsyCoLaus were identiﬁed from a random sample
of all adults aged 35 to 75 years living in the city of Lausanne,
Switzerland (117 161 habitants), and the initial cohort
included 6733 participants (52.5% women).13
For the HypnoLaus study, the ﬁrst 3043 consecutive
participants of the ﬁrst follow-up of the CoLaus/PsyCoLaus
study were invited to have a full PSG at home. Of these, 2168
(71%) accepted the invitation; 60 (3%) had technical problems
and were invited to undergo a second PSG; 6 participants
declined, and 54 participants agreed.8 Therefore, 2162 com-
plete PSG recordings were obtained in the HypnoLaus cohort
and included in this study. The ethics committee of the
University of Lausanne approved the CoLaus/HypnoLaus study.
The study complies with the Declaration of Helsinki, and written
informed consent was obtained from all participants.
Clinical Data Collection
Participants from the CoLaus/HypnoLaus study were invited
to attend the outpatient clinic at the University Hospital of
Lausanne (CHUV, Lausanne, Switzerland) in the morning after
an overnight fast for questionnaire completion, clinical
assessment, and blood sample collection. Body weight and
height were measured using a calibrated scale and a vertical
stadiometer, respectively (Seca, Hamburg, Germany). Systolic
and diastolic blood pressure were evaluated in triplicate on
the left arm at 5-minute intervals with the participant seated
and resting for at least 10 minutes using a calibrated
automated oscillometric sphygmomanometer (Omron HEM-
907, Matsusaka, Japan).14 Overnight fasting blood samples
were taken from the antecubital vein of each participant.
Glucose and total cholesterol were quantiﬁed by colorimetric
assays as previously described.13
These assays were performed within 2 hours on fresh
blood samples by the CHUV Clinical Laboratory (Lausanne,
Switzerland).
Cardiovascular Health
Global CVH was based on and adapted from the 7 metrics
deﬁned by the American Heart Association4: 4 behavioral
(smoking, BMI, diet, physical activity) and 3 biological (fasting
blood glucose, total cholesterol, blood pressure). Global CVH
was measured according to the number of metrics at ideal
level and categorized into poor (0-2), intermediate (3-4), and
ideal (5-7), irrespective of whether subjects had 1 missing
CVH metric. Poor, intermediate, and ideal behavioral CVH
were deﬁned as having 0-1, 2, and 3-4 behavioral metrics at
ideal level, respectively; for biological CVH, these levels were
deﬁned as 0-1, 2, and 3 biological metrics at ideal level. The
deﬁnitions of the CVH metrics are described in Data S1, and
the thresholds and categorization of the CVH metrics are
summarized in Table S1.
Clinical Perspective
What Is New?
• This study conﬁrms that higher oxygen saturation is
associated with better cardiovascular health.
• Respiratory disturbances during sleep and the associated
oxygen (de)saturation are stronger determinants of cardio-
vascular health than sleep architecture or fragmentation.
What Are the Clinical Implications?
• Because respiratory disturbances during sleep are highly
prevalent in the general population and have been found to
be associated with worse cardiovascular health, clinicians
should be educated to expedite diagnosis and treatment.
• Our results suggest that treatment of obstructive sleep
apnea might improve cardiovascular health because the
associated oxygen desaturation was consistently associated
with cardiovascular health.
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Polysomnography
The detailed PSG procedure has been described previously.8
The following PSG measures were used in the analyses: total
sleep time (time spent asleep in minutes from sleep onset to
morning awakening, categorized as <6, 6 to 8, or >8 hours);
stages 1 and2 sleep, slow-wave sleep, and rapid-eye-movement
(REM) sleep (measured as percentage of total sleep time); sleep
efﬁciency (percentage of total time in bed spent asleep); arousal
index (number of arousals measured by electroencephalogram
per hour of total sleep time divided by 5); autonomic arousal
index (number of autonomic arousals measured by pulse wave
amplitude drops of at least 30% of baseline pulse wave ampli-
tude per hour of total sleep time [Figure S1]; pulse wave
amplitude drops were obtained from ﬁnger photoplethysmog-
raphy and reﬂect peripheral vasoconstriction15); autonomic
arousal duration (mean duration of autonomic arousals in
seconds [Figure S1]); periodic limb movement index during
sleep (number of periodic limb movements divided per hours of
sleep); apnea/hypopnea index (AHI) (number of apneas/
hypopneas per hour of sleep); severity of obstructive sleep
apnea (no [AHI<5 per hour], mild [5≤AHI<15 events per hour of
sleep], moderate [15≤AHI<30 events per hour of sleep], or
severe [AHI≥30 events per hour of sleep]); oxygen desaturation
index (number of ≥3% oxygen saturation drops per hour of
sleep); mean oxygen saturation during sleep; and time spent
under 90% oxygen saturation (percentage of total sleep time
spent under a 90% oxygen saturation threshold).
Subjective Sleep Characteristics
Subjective sleep duration was self-reported and categorized
as <6, 6 to 8, and >8 hours. Excessive daytime sleepiness
was evaluated with the Epworth sleepiness scale16 and was
considered to be present with a sum score ≥11.
Exclusion Criteria
Participants were excluded from the analyses if they (1) had a
previous history of cardiovascular disease, (2) lacked infor-
mation for more than 1 CVH metric, (3) lacked information on
sleep characteristics, or (4) lacked information for covariates.
Statistical Analyses
All statistical analyses were performed using STATA 15.1
(Stata-Corp, College Station, TX). To characterize the study
population and to present the prevalence of sleep character-
istics according to their CVH, continuous variables were
summarized as meanSD, and categorical variables as the
number of subjects with column percentages. Pearson chi-
squared (for categorical variables) or ANOVA (for continuous
variables) was used to evaluate differences in sleep charac-
teristics between global CVH categories. Because the pro-
portional odds assumption for ordinal regressions was
violated, we performed multinomial logistic regressions to
assess the effect of sleep characteristics on global, behav-
ioral, and biological CVH and to estimate relative risk ratios.
We adjusted for age, sex, education, and living alone status
and removed the covariates depression, use of sleeping pills,
and alcohol consumption from the ﬁnal analyses, as Akaike
Information Criterion/Bayesian Information Criterion and
likelihood ratio test indicated best model ﬁt.
In order to check for the robustness of the results, we
performed several sensitivity analyses. First, we operational-
ized CVH as a continuous variable with the number of metrics
at ideal level (0-7) and the sum of metrics at poor,
intermediate, or ideal level (score ranging from 0 to 14)
(Table S1). Second, we reconstructed behavioral CVH without
BMI and reran the analyses with and without adjustment for
BMI. Third, we adjusted for depression and for sleeping pill
and alcohol consumption (Data S1). Fourth, we performed
multinomial regression including all sleep characteristics as
explanatory variables for global CVH. Statistical signiﬁcance
was considered for a 2-sided test with P<0.05.
Results
Study Population and Characteristics
Of the initial 2162 subjects undergoing PSG, 336 (15.5%)
were excluded due to previous self-reported history of
cardiovascular disease (n=180), missing information for more
than 1 CVH metric (n=104), or missing information on sleep
characteristics (n=23) and covariates (n=1), resulting in a
sample size of 1826 (84.5%, Figure 1). Excluded subjects
were older, with lower educational levels, more often had
depressive status, and consumed more sleeping pills and less
alcohol than included ones (Table S2).
Table 1 summarizes the characteristics of the study sample
according to the global CVH status. Almost half of the subjects
had poor (46.2%) or intermediate (42.4%) global CVH, and only
11.5% of subjects had ideal global CVH. Subjectswith poor global
CVHweremore frequentlymale, were older, had lower education,
and were less frequently living alone than subjects with
intermediate or ideal global CVH. Subjects with poor global
CVH had shorter total sleep time, spent a higher percentage of
total sleep time in stage 1 and 2, and lower percentages in slow-
wave sleep and REM sleep than subjects with intermediate or
ideal global CVH. They also had poorer sleep efﬁciency, higher
arousal index, lower autonomic arousal index, longer autonomic
arousal duration, and higher periodic limb movement index than
subjects with intermediate or ideal global CVH. Further, subjects
with poor global CVH had higher AHI, a higher oxygen
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desaturation index, lower mean oxygen saturation, and spent
more time under 90% oxygen saturation than did subjects with
intermediate and ideal global CVH. Subjectswith poor global CVH
were more likely to report short (<6 hours) and long (>8 hours)
sleep duration than subjects with intermediate and ideal global
CVH.No statistically signiﬁcant differences for excessive daytime
sleepiness were found between global CVH levels.
Sleep Architecture and CVH
Subjects with a higher percentage of stage 1 sleep were less
likely, and those with a higher percentage of slow-wave sleep
were more likely, to have intermediate global CVH versus poor
CVH (Table 2). Similar associations were found for behavioral
CVH but not for biological CVH (Table 3). Sleep efﬁciency was
only associated with behavioral CVH. Subjects with a higher
arousal index were less likely to have intermediate and ideal
global CVH relative to poor CVH. Similar associations were
found for behavioral and biological CVH. Autonomic arousal
index was not signiﬁcantly related to global CVH, but subjects
with a higher autonomic arousal index were more likely to
have intermediate and ideal behavioral CVH, and conversely
less likely to have intermediate biological CVH, than those
with poor CVH. Subjects with longer autonomic arousals were
more likely to have intermediate global CVH than poor CVH.
Finally, no associations were found between total sleep time,
stage 2, REM, or periodic limb movement index and global,
behavioral, or biological CVH.
Obstructive Sleep Apnea Severity and CVH
Subjects with higher AHI were less likely to have intermediate
and ideal global, behavioural, and biological CVH than thosewith
poorCVH (Tables 2and3). Theassociationswere strongestwith
global CVH, followed by biological and behavioral CVH. Subjects
with more severe obstructive sleep apnea were less likely to
have intermediate and even less likely to have ideal global CVH
than subjects with no obstructive sleep apnea (Figure 2).
Oxygen Saturation–Related Variables and CVH
Subjects with higher oxygen desaturation index and higher time
spent under 90% oxygen saturation were less likely to have
intermediate and ideal global CVH versus poor CVH (Table 2).
These associations were also signiﬁcant for behavioral and
biological CVH, except for time spent under 90% oxygen
saturation and biological CVH (Table 3). The associations were
strongest with global CVH, followed by biological and behavioral
CVH. Moreover, subjects with higher oxygen saturation were
more likely to have better global, behavioral, and biological CVH.
Subjective Sleep Characteristics and CVH
Subjects reporting short sleep duration weremore likely to have
poor global CVH and less likely to have intermediate and ideal
CVHwhencomparedwithsubjects reporting ideal sleepduration
(6-8 hours) (Table 2). Subjects reporting long sleep duration
were also less likely to have ideal global CVH compared with
those reporting ideal sleep duration. Similar results were found
for behavioral but not for biological CVH (Table 3). No relation-
ship between excessive daytime sleepiness and CVHwas found.
Sensitivity Analyses
In the ﬁrst sensitivity analysis, sleep characteristics that were
signiﬁcantly associated with CVH in the main analyses
retained their associations with global CVH scores (0-7 or
0-14) (Table S3). Additionally, autonomic arousal index and
periodic limb movement index were signiﬁcantly associated
with global CVH (0-14). The standardized b coefﬁcients
revealed strongest effects for mean oxygen saturation
followed by oxygen desaturation index and AHI.
In the sensitivity analysis using behavioral CVH without
BMI, only the association between oxygen desaturation index
and intermediate/ideal behavioral CVH (without adjustment
for BMI) remained signiﬁcant, and both mean oxygen
saturation and time spent under 90% oxygen saturation
retained their association with ideal behavioral CVH (with and
without adjustment for BMI). Additionally, both subjective and
PSG-assessed short sleep duration were associated with a
lower relative risk of having ideal behavioral CVH (Table S4).
With Polysomnography 
N=2162 
Final sample 
N=1826 
Missing for sleep variables 
N=51 
Missing 2+ metrics for CVH  
N=104 
Prevalent CVD 
N=180 
Missing for confounders 
N=1 
Figure 1. Flowchart of study population. CVD indicates cardio-
vascular disease; CVH, cardiovascular health.
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In the sensitivity analysis adjusting for depression, sleeping
pills, and alcohol consumption, the sleep characteristics that
were signiﬁcantly associated with CVH in the main analyses
retained their signiﬁcance—except that the association
between stage 1, slow-wave sleep and subjective sleep duration
was no longer associated with global CVH (Table S5).
Table 1. Characteristics of the Subjects According to Cardiovascular Health Levels, HypnoLaus Study, Lausanne, 2009-2013
Cardiovascular Health
P ValuePoor (N=842) Intermediate (N=775) Ideal (N=209)
General characteristics
Men 524 (62.2) 289 (37.3) 67 (32.1) <0.001
Age, y 59.3 (10.0) 55.2 (9.7) 50.5 (8.1) <0.001
Education
High 142 (16.9) 206 (26.6) 68 (32.5) <0.001
Middle 222 (26.4) 232 (29.9) 59 (28.2)
Low 478 (56.8) 337 (43.5) 82 (39.2)
Living alone status 299 (35.5) 352 (45.4) 95 (45.5) <0.001
Alcohol consumption
Never/rare 128 (17.2) 164 (25.1) 45 (26.8) <0.001
1 to 2 drinks per day 595 (80.1) 483 (74.0) 122 (72.6)
3+ drinks per day 20 (2.7) 6 (0.9) 1 (0.6)
Sleeping pills 121 (14.4) 108 (13.9) 32 (15.3) 0.877
Depression 121 (15.4) 95 (13.1) 26 (13.1) 0.395
PSG sleep characteristics
Total sleep time
<6 h 241 (28.6) 176 (22.7) 31 (14.8) 0.001
6 to 8 h 503 (59.7) 494 (63.7) 149 (71.3)
>8 h 98 (11.6) 105 (13.6) 29 (13.9)
Stage 1 (% of TST) 13.17.6 10.76.2 9.84.2 <0.001
Stage 2 (% of TST) 46.710.3 45.59.8 45.08.0 0.005
Slow-wave sleep (% of TST) 18.78.5 21.18.0 21.87.8 <0.001
Rapid eye movement (% of TST) 21.56.1 22.75.5 23.35.7 <0.001
Sleep efficiency (%) 83.810.5 86.310.0 88.18.5 <0.001
Arousal index 23.511.9 19.09.0 16.67.3 <0.001
Autonomic arousal index 63.0 (23.6) 66.1 (23.1) 71.7 (23.1) <0.001
Autonomic arousal duration 14.6 (3.3) 13.8 (2.8) 13.6 (2.7) <0.001
Periodic limb movement index 16.225.1 10.519.1 7.814.2 <0.001
Apnea/hypopnea index 20.218.5 10.911.6 6.77.9 <0.001
Obstructive sleep apnea severity
No (AHI<5/h) 135 (16.0) 282 (36.4) 127 (60.8) <0.001
Mild (5≤AHI<15/h) 289 (34.3) 311 (40.1) 56 (26.8)
Moderate (15≤AHI<30/h) 232 (27.6) 128 (16.5) 20 (9.6)
Severe (AHI≥30/h) 186 (22.1) 54 (7.0) 6 (2.9)
Oxygen desaturation index 1.51.8 0.61.0 0.30.6 <0.001
Mean oxygen saturation 93.51.8 94.61.6 95.41.2 <0.001
SpO2<90 6.1 (14.6) 2.0 (8.7) 0.4 (2.2) <0.001
Continued
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Conversely, the periodic limbmovement index was signiﬁcantly
associated with intermediate CVH.
When all sleep characteristics were included as explanatory
variables for CVH, mean oxygen saturation was signiﬁcantly
associated with intermediate and ideal CVH. The associations
between oxygen desaturation index and ideal CVH as well as
autonomic arousal duration and intermediate CVH remained
signiﬁcant. The periodic limb movement index was additionally
associated with intermediate CVH (Table S5).
Finally, when sex-stratiﬁed analyses were performed and
included age squared as a covariate, the results remained
stable (results not shown).
Discussion
To our knowledge, this is the ﬁrst population-based study
investigating the association between objective PSG-derived
and subjective sleep characteristics and CVH. We found that
all variables related to respiratory disturbances—especially
those associated with oxygen (de)saturation—were strongly
associated with global, behavioral, and biological CVH.
Sleep-Disordered Breathing and Oxygen
(De) saturation
We found strong dose-response relationships between sleep-
disordered breathing and associated oxygen saturation vari-
ables with CVH. Subjects with more severe obstructive sleep
apnea (and higher AHI) were less likely to have high levels of
global, behavioral, and biological CVH. Interestingly, the
association between AHI and CVH became nonsigniﬁcant after
adjustment for variables related to oxygen saturation. Obstruc-
tive sleep apnea is associated with increased sympathetic
activity17 and is characterized by intermittent hypoxia. Hypox-
emia has been linked to endothelial dysfunction,18 arterial
stiffness,19 and oxidative stress,7,20,21 which are possible
underlying mechanisms by which obstructive sleep apnea
affects the cardio- and cerebrovascular systems. Our ﬁndings
that mean oxygen saturation, oxygen desaturation index, and
time spent under 90% oxygen saturation were gradually and
consistently associated with global, behavioral, and biological
CVH are in line with previous studies linking these oxygen
saturation–related variables with glucose intolerance, hyper-
tension, increased cholesterol, and obesity.12,22,23 Moreover,
sensitivity analyses revealed that mean oxygen saturation and
oxygen desaturation index had the strongest and most robust
effects on CVH. Hence, mean oxygen saturation and oxygen
desaturation index probably explained the association between
other sleep characteristics (stage 1, slow-wave sleep, arousal
index, and AHI) and CVH.
Sleep Architecture
Although stage 1 and slow-wave sleep were associated with
global and behavioral CVH, these associations were not
robust in regard to sensitivity analyses. Because obese people
suffer more often from obstructive sleep apnea and conse-
quently have more awakenings during the night, they shift
more frequently from slow-wave sleep and REM to light sleep
(ie, stages 1 and 2). This suggests that obstructive sleep
apnea may be responsible for these results.
Arousal index measured by electroencephalogram was
consistently and inversely related to global, biological, and
behavioral CVH. The increased sympathetic activity resulting
from arousals (and also from hypoxia) can lead to vasocon-
striction and has been linked to hypertension, diabetesmellitus,
and dyslipidemia17—all of which are components of CVH.
Pulse-wave amplitude drops associated with autonomic
arousals probably reﬂect vessel contractility15. Previous
studies reported inverse associations between pulse-wave
amplitude drops index and CV risk in patients with sleep-
disordered breathing24 and in those with obstructive sleep
apnea treated with CPAP.25 Our ﬁnding that an autonomic
arousal index was positively related to biological CVH and that
Table 1. Continued
Cardiovascular Health
P ValuePoor (N=842) Intermediate (N=775) Ideal (N=209)
Subjective sleep characteristics
Subjective sleep duration*
<6 h 89 (10.7) 58 (7.6) 12 (5.7) 0.002
6 to 8 h 666 (79.9) 645 (84.0) 190 (90.9)
>8 h 79 (9.5) 65 (8.5) 7 (3.4)
Excessive daytime sleepiness† 106 (13.2) 106 (14.2) 26 (12.9) 0.817
N (%) or mean (SD). P values from Pearson chi squared or ANOVA when appropriate. AHI indicates apnea/hypopnea index; PSG, polysomnography; SpO2<90, percentage of total sleep time
spent under a 90% oxygen saturation threshold; TST; total sleep time.
*N=1811; †N=1750.
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autonomic arousal duration was inversely related to global
CVH suggests that frequent and quickly reversible vasocon-
strictions are related to increased CVH levels. However, the
association between autonomic arousal index and behavioral
CVH was unstable, and this hypothesis still needs to be
further investigated by prospective studies. Surprisingly,
autonomic arousal duration was not negatively associated
with ideal CVH. A possible hypothesis is residual confounding
because favorable health behaviors tend to cluster in subjects
with ideal CVH26. These unmeasured health behaviors could
affect autonomic arousal duration.
Although periodic limb movement index was not associ-
ated with global, behavioral, and biological CVH, the periodic
limb movement index had signiﬁcant effects on global CVH,
when additional variables (depression, sleeping pills, alcohol
consumption, and other sleep characteristics) were included
in the model suggesting interactions with these additional
variables. Our unstable ﬁndings regarding stage 1, slow-wave
sleep, and arousal measures and the lack of a relationship
between total sleep time, stage 2, and REM and CVH are in
line with a previous study that found no association between
sleep architecture and cardiovascular risk factors.11 Because
most variables related to sleep architecture were not
consistently related to CVH, we conclude that sleep structure
and sleep fragmentation have minor effects on CVH.
Implications
Sleep disorders are highly prevalent in the population7-9
and have adverse effects on cardiovascular disease.7,10
Table 2. Multivariable Analysis of the Associations Between Sleep Characteristics and Global Cardiovascular Health for Each
Variable Separately, Adjusted for Age, Sex, Education, and Marital Status; HypnoLaus study, Lausanne, 2009-2013 (N=1826)
Cardiovascular Health (Poor=Ref.)
Intermediate Ideal
RRR (95% CI) P Value RRR (95% CI) P Value
PSG sleep characteristics
Total sleep time
6 to 8 h (Ref.) 1 1
<6 h 1.05 (0.82-1.35) 0.701 0.74 (0.48-1.16) 0.189
>8 h 0.96 (0.69-1.32) 0.790 0.83 (0.51-1.34) 0.442
Stage 1 (% of TST) 0.98 (0.96-1.00) 0.026 0.97 (0.94-1.00) 0.068
Stage 2 (% of TST) 1.00 (0.99-1.01) 0.477 1.00 (0.98-1.02) 0.924
Slow-wave sleep (% of TST) 1.02 (1.00-1.03) 0.021 1.02 (1.00-1.04) 0.129
Rapid eye movement (% of TST) 1.00 (0.99-1.02) 0.599 1.00 (0.97-1.03) 0.871
Sleep efficiency 1.00 (0.99-1.01) 0.908 1.00 (0.98-1.02) 0.834
Arousal index† 0.91 (0.86-0.96) <0.001 0.82 (0.74-0.91) <0.001
Autonomic arousal index† 1.00 (0.97-1.02) 0.764 1.02 (0.98-1.06) 0.296
Autonomic arousal duration 0.96 (0.92-0.99) 0.017 0.98 (0.92-1.05) 0.633
Periodic limb movement index 1.00 (0.99-1.00) 0.127 1.00 (0.99-1.01) 0.510
Apnea/hypopnea index‡ 0.75 (0.69-0.82) <0.001 0.55 (0.44-0.68) <0.001
Oxygen desaturation index‡ 0.71 (0.65-0.78) <0.001 0.45 (0.34-0.58) <0.001
Mean oxygen saturation (SpO2) 1.31 (1.22-1.41) <0.001 1.78 (1.55-2.04) <0.001
SpO2<90 0.97 (0.96-0.98) <0.001 0.85 (0.77-0.94) 0.001
Subjective sleep characteristics
Sleep duration§
6 to 8 h (ref.) 1 1
<6 h 0.68 (0.47-0.99) 0.044 0.48 (0.25-0.94) 0.031
>8 h 0.94 (0.65-1.38) 0.767 0.39 (0.17-0.90) 0.028
Excessive daytime sleepinessk 0.97 (0.71-1.33) 0.868 0.71 (0.44-1.17) 0.181
PSG indicates polysomnography; Ref., reference value; RRR, relative risk ratio; SpO2<90, percentage of total sleep time spent under a 90% oxygen saturation threshold; TST, total sleep
time. N’s for poor: N=842, intermediate: N=775, ideal: N=209.
†Divided by 5. ‡Divided by 10. §N=1811. kN=1750.
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Hence, both clinicians and the public in general should be
educated about sleep disorders to expedite diagnosis and
treatment.27 Treatment of obstructive sleep apnea might be
a mean to improve CVH, as variables associated with
oxygen saturation were consistently associated with global,
behavioural, and biological CVH. This is of great public
health relevance, since the modiﬁcations of the highly
prevalent cardiovascular risk factors forming biological CVH
otherwise require pharmacological intervention. However,
the effect of obstructive sleep apnea treatment on cardio-
vascular disease has not been established21 and prospec-
tive randomized studies should ﬁll this gap in our clinical
knowledge.
Limitations
We acknowledge several limitations. First, because Hypno-
Laus is a monocentric study focusing on middle-aged and
Table 3. Multivariable Analysis of the Associations Between Sleep Characteristics and Behavioral and Biological Cardiovascular
Health for Each Variable Separately, Adjusted for Age, Sex, Education, and Marital Status; HypnoLaus Study, Lausanne, 2009-2013
Behavioral Cardiovascular Health (Poor=Ref.) Biological Cardiovascular Health (Poor=Ref.)
Intermediate Ideal Intermediate Ideal
RRR P Value RRR P Value RRR P Value RRR P Value
PSG sleep characteristics
Total sleep time
6 to 8 h (Ref.) 1 1 1 1
<6 h 0.89 (0.69-1.13) 0.338 0.73 (0.51-1.03) 0.069 0.95 (0.70-1.28) 0.725 1.47 (0.89-2.43) 0.137
>8 h 0.78 (0.57-1.08) 0.134 0.76 (0.50-1.14) 0.187 1.15 (0.82-1.61) 0.426 1.13 (0.64-2.01) 0.671
Stage 1 (% of TST) 0.98 (0.97-1.00) 0.046 0.96 (0.94-0.98) 0.002 1.00 (0.98-1.02) 0.854 0.98 (0.94-1.02) 0.312
Stage 2 (% of TST) 1.00 (0.99-1.01) 0.941 1.01 (0.99-1.02) 0.286 0.99 (0.98-1.00) 0.220 0.99 (0.97-1.02) 0.640
Slow-wave sleep
(% of TST)
1.01 (1.00-1.03) 0.029 1.01 (1.00-1.03) 0.097 1.01 (0.99-1.02) 0.294 1.01 (0.99-1.04) 0.327
Rapid eye movement
(% of TST)
0.99 (0.98-1.01) 0.580 0.99 (0.97-1.02) 0.562 1.01 (0.99-1.03) 0.458 1.01 (0.97-1.05) 0.752
Sleep efficiency 0.99 (0.98-1.00) 0.049 1.00 (0.99-1.02) 0.660 1.01 (1.00-1.03) 0.082 0.98 (0.96-1.00) 0.119
Arousal index† 0.94 (0.90-0.99) 0.025 0.88 (0.82-0.95) 0.001 0.91 (0.85-0.97) 0.005 0.82 (0.71-0.94) 0.004
Autonomic arousal index† 1.03 (1.01-1.06) 0.010 1.04 (1.00-1.07) 0.026 0.97 (0.95-1.00) 0.044 1.03 (0.98-1.08) 0.298
Autonomic arousal
duration
0.97 (0.94-1.00) 0.069 0.98 (0.94-1.03) 0.458 0.98 (0.93-1.02) 0.254 0.96 (0.88-1.05) 0.353
Periodic limb movement
index
1.00 (0.99-1.00) 0.223 1.00 (0.99-1.00) 0.429 1.00 (0.99-1.00) 0.398 0.99 (0.98-1.01) 0.405
Apnea/hypopnea index‡ 0.84 (0.78-0.91) <0.001 0.66 (0.57-0.76) <0.001 0.80 (0.71-0.89) <0.001 0.57 (0.41-0.79) 0.001
Oxygen desaturation
index‡
0.82 (0.76-0.89) <0.001 0.59 (0.50-0.69) <0.001 0.76 (0.67-0.86) <0.001 0.52 (0.37-0.75) <0.001
Mean oxygen saturation
(SpO2)
1.19 (1.11-1.27) <0.001 1.71 (1.53-1.91) <0.001 1.18 (1.09-1.28) <0.001 1.37 (1.17-1.61) <0.001
SpO2<90 0.99 (0.98-1.00) 0.012 0.88 (0.83-0.93) <0.001 0.98 (0.97-1.00) 0.052 0.91 (0.82-1.01) 0.080
Subjective sleep characteristics
Sleep duration§
6 to 8 h (Ref.) 1 1 1 1
<6 h 0.60 (0.41-0.87) 0.007 0.66 (0.40-1.08) 0.095 0.69 (0.44-1.06) 0.090 0.73 (0.34-1.54) 0.408
>8 h 0.93 (0.65-1.34) 0.697 0.45 (0.24-0.83) 0.010 0.79 (0.50-1.25) 0.313 0.39 (0.13-1.11) 0.078
Excessive daytime
sleepinessk
0.76 (0.56-1.04) 0.084 0.77 (0.51-1.16) 0.210 1.03 (0.74-1.45) 0.849 1.07 (0.62-1.84) 0.802
PSG indicates polysomnography; Ref., reference value; RRR, relative risk ratio; SpO2<90, percentage of total sleep time spent under a 90% oxygen saturation threshold; TST, total sleep time. For
behavioral CVH: Poor (N=758), intermediate (N=751), Ideal (N=317). For biological CVH: Poor (N=1251), Intermediate (N=454), Ideal (N=121).
†Divided by 5. ‡Divided by 10. §N=1811. kN=1750.
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elderly subjects, the external validity might be limited to
similar aged populations. Second, we had to adapt the
smoking and diet metrics as deﬁned by the American Heart
Association due to limited information (see Data S1 for
more detail). However, such adaptions have previously been
used and have yielded consistent results compared with the
original American Heart Association CVH score.28 Third,
although PSG is the gold standard for sleep studies, the
recording of a single night cannot account for night-to-night
variability. In order to limit this so-called “ﬁrst-night effect,”
PSG was performed at home, and 20 randomly selected
participants underwent a second PSG at home to determine
short-term variability. Only, the percentage of total sleep
time spent in REM differed between the 2 nights
(21.46.7% versus 245%, P=0.04). Finally, due to the
cross-sectional design, causal inferences can only be drawn
with caution, and future longitudinal studies are needed to
conﬁrm the observed effects. Further, longitudinal studies
should also assess whether the associations between sleep
characteristics and CVH are bidirectional because effects of
cardiovascular risk factors such as diabetes mellitus,
dyslipidemia, hypertension, or obesity on sleep have been
established.7,29
In conclusion, higher oxygen saturation was associated
with better CVH, whereas having a higher oxygen desatu-
ration index and AHI were associated with worse CVH. Our
results suggest that respiratory disturbances during sleep
and their associated oxygen (de)saturation are stronger
determinants of CVH than sleep architecture or sleep
fragmentation.
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Data S1. 
 
Cardiovascular health metrics in CoLaus/HypnoLaus 
Smoking status was adapted from the American Heart Association criteria, as time since 
smoking cessation was not available. Ideal smoking status was assigned to subjects that never smoked.  
Body mass index (BMI) was categorized according to AHA criteria, with ideal BMI 
corresponding to a value <25 kg/m2. 
Physical activity was assessed by the physical activity frequency questionnaire (PAFQ), which 
has been validated in the population of Geneva 1. This self-reported questionnaire assesses the type and 
duration of 70 kinds of (non)professional activities and sports during the previous week. We summed 
up the duration of all walking items including slow cycling and considered fast/uphill walking as 
vigorous activity together with all other sports assessed in the questionnaire. We counted the frequency 
of sports (incl. fast/uphill walking) per week and categorized subjects as having ideal physical activity, 
when subjects reported to either walk more than one hour daily or practicing sports at least three times 
per week. 
Dietary intake was assessed using a self-administered, semi-quantitative food frequency 
questionnaire (FFQ) 2, which has been validated in the Geneva population 2,3. Briefly, this FFQ assesses 
the frequency of 97 different food items of the previous 4 weeks 4. We adapted the diet measure from 
the AHA criteria 5 as sodium intake was not available in CoLaus. Hence, the diet metric was constructed 
from the intake of fruits and vegetables, fiber, fish and sugar-sweetened beverages. Subjects reporting 
to consume at least 787 g/day fruits and vegetables, at least 85g/day of fiber-rich whole grains, at least 
198 g/week fish and less than 153 ml/day of sugar-sweetened beverages were considered as having an 
ideal diet. 
Ideal total cholesterol and ideal fasting plasma glucose were defined as untreated values <5.18 
mmol/L and <5.55 mmol/L, respectively. Ideal blood pressure was defined as untreated values <120 
mm Hg and <80 mm Hg for systolic and diastolic blood pressure, respectively. All three biological 
measures correspond to the AHA criteria.  
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Covariates 
 
Education level was categorized as low (mandatory education or apprenticeship), intermediate 
(high school diploma) and high (university diploma). Depressive status was measured with the 
previously validated 20-item CES-D questionnaire, and subjects were considered as presenting a 
depressive status when having a sum score of at least 17 for men and 23 for women6. Alcohol 
consumption was categorized as never/less than daily, one or two glasses per day and three or more 
glasses per day. Consumption of prescribed and over the counter sleep medications was self-reported 
(yes/no). 
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Table S1. CVH metrics as defined by AHA and as used in CoLaus/HypnoLaus. 
Metric  Poor Intermediate Ideal 
Smoking status     
AHA  Current smoker Former smoker, <12 months Never or quit >12 months 
CoLaus  Current smoker Former smoker Never smoker 
Body mass index     
AHA  ≥30 kg/m2 25–29.9 kg/m2 <25 kg/m2 
CoLaus  ≥30 kg/m2 25–29.9 kg/m2 <25 kg/m2 
Physical activity     
AHA  None 1–149 min/week moderate intensity or  
1–74 min/week vigorous intensity or  
1–149 min/week moderate + vigorous 
≥150 min/week moderate intensity or  
≥75 min/week vigorous intensity or 
≥150 min/week moderate + vigorous 
CoLaus  <1 h/ daily, <1 sports weekly <1 h/day walking and 1-2 times sports 
weekly 
≥1 h/day or thrice sports weekly 
Healthy diet score     
AHA  
      
 
fruits/veg. ≥ 4.5 cups/day 
fish ≥twice 3.5oz/week 
fiber-rich whole grains≥3 oz/day 
sodium <1500 mg/day 
sw. beverages ≤ 36 oz/week 
0–1 ideal components 2–3 ideal components 4–5 ideal components 
CoLaus 
 
fruits/veg. ≥ 787.5 g/day 
fish ≥198 g/week 
fiber-rich whole grains ≥85 g/day 
sw. beverages ≤1064 ml/week 
0–1 ideal components 2–3 ideal components 4 ideal components 
Total cholesterol     
AHA  ≥240 mg/dL 200–239 mg/dL or treated to goal <200 mg/dL 
CoLaus  ≥6.22 mmol/L 5.18-6.21 mmol/L or <5.18 mmol/L on 
medications 
<5.18 mmol/L free of medication 
Blood pressure     
AHA  SBP ≥140 or DBP ≥90 mm Hg SBP 120–139 or DBP 80–89 mm Hg or 
treated to goal 
SBP <120 and DBP<80 mm Hg 
CoLaus  SBP ≥140 or DBP ≥90 mm Hg SBP 120–139 or DBP 80–89 mm Hg or 
<120/80 mm Hg on medication 
SBP <120 and DBP<80 mm Hg free of 
medication 
Fasting plasma glucose     
AHA  ≥ 126 mg/dL 100–125 mg/dL or treated to goal <100 mg/dL 
CoLaus  ≥ 6.99 mmol/L 5.55-6.98 mmol/L or  
<5.55 mmol/L on medication 
< 5,55 mmol/L free of medication 
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Table S2. Characteristics of the included and excluded subjects. 
 Included (n=1826) Excluded (n=336) p-value 
Male sex 880 (48.2) 176 (52.4) 0.158 
Age (years)* 56.6 ± 10.1 63.8 ± 10.9 <0.001 
Education level   <0.001 
Low 897 (49.1) 210 (62.9)  
Middle 513 (28.1) 76 (22.8)  
High 416 (22.8) 48 (14.4)  
Living alone 756 (40.9) 139 (43.4) 0.387 
Alcohol    0.027 
Never/rare 337 (21.6) 70 (26.6)  
1-2 drinks/day 1200 (76.7) 184 (70.0)  
≥3 drinks/day 27 (1.7) 9 (3.4)  
Depression 242 (14.2) 42 (19.6) 0.035 
Sleeping pills 261 (14.3) 78 (23.2) <0.001 
N (%) or * mean ± SD. P-values from Pearson chi2 or ANOVA when appropriate 
 
D
ow
nloaded from
 http://ahajournals.org by on March 25, 2019
 
 
Table S3. Results of sensitivity analyses for multivariate linear regression: effect of sleep 
characteristics on cardiovascular health measured as continuous variable ranging from 0-7 and 
0-14. 
§ divided by 5; || divided by 10; 1 N=1811 2 N=1750 
* Percentage of total sleep time spent under a 90% oxygen saturation threshold 
Results are expressed as standardized regression coefficients
 Cardiovascular health (0-7) Cardiovascular health (0-14) 
 Beta p-value Beta p-value 
Total sleep time     
   6-8h (ref.) 0  0  
  <6h -0.015 0.485 -0.021 0.352 
   >8h -0.016 0.454 -0.014 0.537 
Stage 1 -0.069 0.002 -0.087 <0.001 
Stage 2 0.001 0.969 -0.009 0.667 
Slow wave sleep 0.049 0.024 0.059 0.008 
Rapid eye movement 0.005 0.807 0.028 0.212 
Sleep efficiency -0.015 0.513 -0.021 0.363 
Arousal index§ -0.104 <0.001 -0.124 <0.001 
Autonomic arousal index§ 0.023 0.297 0.063 0.006 
Autonomic arousal duration -0.043 0.048 -0.014 0.523 
Periodic limb movement index -0.030 0.176 -0.061 0.008 
Apnea/hypopnea index|| -0.184 <0.001 -0.218 <0.001 
Oxygen desaturation index|| -0.201 <0.001 -0.239 <0.001 
Mean oxygen saturation (SpO2) 0.241 <0.001 0.280 <0.001 
SpO2<90* -0.111 <0.001 -0.139 <0.001 
Subj. sleep duration1     
   6-8h (ref.) 0  0  
  <6h -0.056 0.008 -0.046 0.034 
   >8h -0.041 0.055 -0.054 0.013 
Excessive daytime sleepiness 2 -0.011 0.621 -0.024 0.288 
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Table S4. Results of sensitivity analyses for multinomial logistic regressions: Effects of sleep characteristics on behavioral CVH constructed without 
BMI 1) and no adjustment 2) with adjustment for BMI. 
 Behavioral CVH without BMI (poor=ref) Behavioral CVH without BMI (poor=ref) – adjusted for BMI 
 Intermediate Ideal Intermediate Ideal 
 RRR p-value RRR p-value RRR p-value RRR p-value 
Total sleep time         
   6-8h (ref.) 1  1  1  1  
  <6h 0.97 (0.69 - 1.36) 0.853 0.63 (0.43 - 0.91) 0.014 0.96 (0.68 - 1.35) 0.818 0.62 (0.43 - 0.91) 0.013 
   >8h 0.69 (0.44 - 1.07) 0.094 0.72 (0.46 - 1.14) 0.162 0.71 (0.45 - 1.10) 0.121 0.75 (0.47 - 1.19) 0.222 
Stage1 0.98 (0.96 – 1.00) 0.082 0.98 (0.96 – 1.00) 0.062 0.99 (0.97 - 1.01) 0.203 0.99 (0.96 - 1.01) 0.188 
Stage2 1.00 (0.99 - 1.02) 0.812 1.01 (0.99 - 1.02) 0.487 1.00 (0.99 - 1.02) 0.805 1.01 (0.99 - 1.02) 0.466 
Slow wave sleep 1.01 (0.99 - 1.03) 0.228 1.01 (0.99 - 1.03) 0.504 1.01 (0.99 - 1.03) 0.411 1.00 (0.98 - 1.02) 0.829 
Rapid eye movement 1.00 (0.98 - 1.03) 0.954 1.00 (0.98 - 1.03) 0.831 1.00 (0.98 - 1.03) 0.976 1.00 (0.98 - 1.03) 0.882 
Sleep efficiency 0.99 (0.98 - 1.01) 0.517 0.99 (0.98 - 1.01) 0.531 0.99 (0.98 - 1.01) 0.457 0.99 (0.98 - 1.01) 0.468 
Arousal index§ 0.98 (0.91 - 1.05) 0.490 0.98 (0.91 - 1.05) 0.500 1.00 (0.93 - 1.07) 0.999 1.01 (0.93 - 1.08) 0.859 
Autonomic arousal index§ 1.01 (0.97 - 1.04) 0.742 1.03 (1.00 - 1.07) 0.085 1.00 (0.97 - 1.04) 0.890 1.03 (0.99 - 1.06) 0.145 
Autonomic arousal duration 0.98 (0.93 - 1.03) 0.388 1.01 (0.96 - 1.06) 0.843 0.99 (0.94 - 1.03) 0.575 1.01 (0.96 - 1.07) 0.596 
Periodic limb movement index 1.00 (0.99 – 1.00) 0.360 1.00 (0.99 - 1.01) 0.907 1.00 (0.99 - 1.00) 0.539 1.00 (0.99 - 1.01) 0.632 
Apnea/hypopnea index|| 0.92 (0.84 – 1.00) 0.060 0.91 (0.83 - 1.01) 0.063 0.96 (0.88 - 1.06) 0.447 0.98 (0.88 - 1.08) 0.678 
Oxygen desaturation index|| 0.89 (0.81 - 0.97) 0.011 0.90 (0.81 - 0.99) 0.036 0.94 (0.85 - 1.03) 0.192 0.98 (0.88 - 1.09) 0.653 
Mean oxygen saturation (SpO2) 1.07 (0.98 - 1.16) 0.140 1.20 (1.10 - 1.32) <0.001 1.01 (0.92 - 1.11) 0.774 1.14 (1.03 - 1.26) 0.013 
SpO2<90* 1.00 (0.99 - 1.01) 0.485 0.98 (0.96 - 0.99) 0.001 1.00 (0.99 - 1.01) 0.884 0.98 (0.97 - 0.99) 0.009 
Subj. sleep duration1         
   6-8h (ref.) 1  1  1  1  
  <6h 0.72 (0.45 - 1.15) 0.174 0.57 (0.34 - 0.96) 0.033 0.75 (0.47 - 1.20) 0.229 0.60 (0.36 - 1.01) 0.053 
   >8h 0.87 (0.53 - 1.43) 0.582 0.71 (0.41 - 1.22) 0.213 0.90 (0.54 - 1.49) 0.677 0.74 (0.43 - 1.28) 0.285 
Excessive daytime sleepiness 2 1.05 (0.67 - 1.65) 0.831 0.87 (0.54 - 1.40) 0.560 1.07 (0.68 - 1.69) 0.764 0.89 (0.55 - 1.44) 0.637 
§ divided by 5; || divided by 10; 1 N=1811 2 N=1750 
* Percentage of total sleep time spent under a 90% oxygen saturation threshold 
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Table S5. Results of sensitivity analyses for multinomial logistic regressions: Effect of sleep characteristics on global CVH with adjustment for 1) 
depression, sleeping pills and alcohol (n=1469) and 2) all sleep characteristics (n=1741). 
 Global CVH (poor=ref) † Global CVH (poor=ref) ǂ 
 Intermediate Ideal Intermediate Ideal 
 RRR p-value RRR p-value RRR p-value RRR p-value 
Total sleep time         
   6-8h (ref.) 1  1  1  1  
  <6h 1.00 (0.76 - 1.33) 0.992 0.70 (0.43 - 1.15) 0.160 1.04 (0.77 - 1.40) 0.810 0.73 (0.43 - 1.22) 0.226 
   >8h 1.04 (0.71 - 1.54) 0.828 0.98 (0.55 - 1.73) 0.945 1.06 (0.75 - 1.51) 0.727 1.12 (0.67 - 1.89) 0.664 
Stage1 0.99 (0.97 - 1.01) 0.319 0.98 (0.94 - 1.01) 0.207 0.82 (0.18 - 3.83) 0.805 0.66 (0.09 - 4.79) 0.682 
Stage2 0.99 (0.98 – 1.00) 0.178 1.00 (0.98 - 1.02) 0.956 0.83 (0.18 - 3.84) 0.808 0.66 (0.09 - 4.82) 0.686 
Slow wave sleep 1.02 (1.00 - 1.03) 0.043 1.01 (0.99 - 1.04) 0.285 0.83 (0.18 - 3.86) 0.813 0.67 (0.09 - 4.84) 0.690 
Rapid eye movement 1.01 (0.98 - 1.03) 0.589 1.00 (0.96 - 1.03) 0.924 0.82 (0.18 - 3.82) 0.804 0.65 (0.09 - 4.71) 0.669 
Sleep efficiency 1.00 (0.98 - 1.01) 0.506 1.00 (0.97 - 1.02) 0.737 1.00 (0.98 - 1.01) 0.828 0.99 (0.97 - 1.02) 0.463 
Arousal index§ 0.92 (0.87 - 0.98) 0.009 0.85 (0.76 - 0.95) 0.004 1.04 (0.96 - 1.13) 0.348 0.92 (0.81 - 1.06) 0.260 
Autonomic arousal index§ 1.00 (0.98 - 1.03) 0.909 1.02 (0.97 - 1.06) 0.422 0.99 (0.96 - 1.01) 0.319 1.01 (0.97 - 1.05) 0.664 
Autonomic arousal duration 0.94 (0.91 - 0.98) 0.004 0.99 (0.93 - 1.06) 0.851 0.94 (0.91 - 0.98) 0.005 0.95 (0.89 - 1.02) 0.188 
Periodic limb movement index 0.99 (0.99 – 1.00) 0.026 1.00 (0.98 - 1.01) 0.457 0.99 (0.99 – 1.00) 0.038 1.00 (0.99 - 1.01) 0.874 
Apnea/hypopnea index|| 0.78 (0.71 - 0.86) <0.001 0.61 (0.49 - 0.76) <0.001 0.87 (0.69 - 1.09) 0.225 1.02 (0.66 - 1.58) 0.930 
Oxygen desaturation index|| 0.74 (0.67 - 0.82) <0.001 0.51 (0.39 - 0.67) <0.001 0.87 (0.68 - 1.11) 0.267 0.58 (0.35 - 0.97) 0.037 
Mean oxygen saturation (SpO2) 1.35 (1.24 - 1.47) <0.001 1.79 (1.54 - 2.09) <0.001 1.27 (1.15 - 1.41) <0.001 1.59 (1.35 - 1.87) <0.001 
SpO2<90* 0.97 (0.95 - 0.98) <0.001 0.84 (0.75 - 0.94) 0.004 1.00 (0.99 - 1.02) 0.500 1.00 (0.94 - 1.06) 0.971 
Subj. sleep duration1         
   6-8h (ref.) 1  1  1  1  
  <6h 0.66 (0.43 - 1.01) 0.056 0.53 (0.26 - 1.10) 0.089 0.74 (0.50 - 1.10) 0.140 0.57 (0.29 - 1.14) 0.113 
   >8h 0.97 (0.62 - 1.53) 0.905 0.40 (0.15 - 1.07) 0.068 1.03 (0.68 - 1.56) 0.893 0.42 (0.18 - 1.02) 0.054 
Excessive daytime sleepiness 2 1.06 (0.75 - 1.51) 0.726 0.68 (0.38 - 1.22) 0.197 1.06 (0.76 - 1.48) 0.714 0.83 (0.50 - 1.40) 0.490 
§divided by 5; || divided by 10; 1 1) N=1461 2 1) N= 1428  
† adjusting for depression, sleeping pills and alcohol; ǂ adjusting for all sleep characteristics; * Percentage of total sleep time spent under a 90% oxygen 
saturation threshold 
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Figure S1. Measurement of pulse wave amplitude drops of at least >30% of baseline pulse wave 
amplitude. 
 
 
EEG: Electroencephalography
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